Linked Life Data

11877285

Source:http://linkedlifedata.com/resource/pubmed/id/11877285

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11877285rdf:typepubmed:Citationlld:pubmed
pubmed-article:11877285lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C0019733lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C1332717lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C1706438lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C0085358lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C0282580lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C1332080lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C0041361lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C1413244lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C2698600lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C0679622lld:lifeskim
pubmed-article:11877285lifeskim:mentionsumls-concept:C0205314lld:lifeskim
pubmed-article:11877285pubmed:issue6lld:pubmed
pubmed-article:11877285pubmed:dateCreated2002-3-5lld:pubmed
pubmed-article:11877285pubmed:abstractTextOncogenic anaplastic lymphoma kinase (ALK) fusion proteins (NPM/ALK and associated variants) are expressed in about 60% of anaplastic large cell lymphomas (ALCLs) but are absent in normal tissues. In this study, we investigated whether ALK, which is expressed at high levels in lymphoma cells, could be a target for antigen-specific cell-mediated immunotherapy. A panel of ALK-derived peptides was tested for their binding affinity to HLA-A*0201 molecules. Binding peptides were assessed for their capacity to elicit a specific immune response mediated by cytotoxic T lymphocytes (CTLs) both in vivo, in HLA-A*0201 transgenic mice, and in vitro in the peripheral blood lymphocytes (PBLs) from healthy donors. Two HLA-A*0201-restricted CTL epitopes, p280-89 (SLAMLDLLHV) and p375-86 (GVLLWEIFSL), both located in the ALK kinase domain were identified. The p280-89- and p375-86-induced peptide-specific CTL lines were able to specifically release interferon-gamma (IFN-gamma) on stimulation with ALK peptide-pulsed autologous Epstein-Barr virus-transformed B cells (LCLs) or T2 cells. Anti-ALK CTLs lysed HLA-matched ALCL and neuroblastoma cell lines endogenously expressing ALK proteins. CTL activity was inhibited by anti-HLA-A2 monoclonal antibody CR11.351, consistent with a class I-restricted mechanism of cytotoxicity. These results show the existence of functional anti-ALK CTL precursors within the peripheral T-cell repertoire of healthy donors, clearly indicating ALK as a tumor antigen and ALK-derived peptides, p280-89 and p375-86, as suitable epitopes for the development of vaccination strategies.lld:pubmed
pubmed-article:11877285pubmed:languageenglld:pubmed
pubmed-article:11877285pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:citationSubsetAIMlld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11877285pubmed:statusMEDLINElld:pubmed
pubmed-article:11877285pubmed:monthMarlld:pubmed
pubmed-article:11877285pubmed:issn0006-4971lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:Gambacorti-Pa...lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:LemonnierFran...lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:ScardinoAnton...lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:PassoniLorena...lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:BertazzoliCar...lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:GalloBarbaraBlld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:ColucciaAddol...lld:pubmed
pubmed-article:11877285pubmed:authorpubmed-author:Kosmatopoulos...lld:pubmed
pubmed-article:11877285pubmed:issnTypePrintlld:pubmed
pubmed-article:11877285pubmed:day15lld:pubmed
pubmed-article:11877285pubmed:volume99lld:pubmed
pubmed-article:11877285pubmed:ownerNLMlld:pubmed
pubmed-article:11877285pubmed:authorsCompleteYlld:pubmed
pubmed-article:11877285pubmed:pagination2100-6lld:pubmed
pubmed-article:11877285pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:meshHeadingpubmed-meshheading:11877285...lld:pubmed
pubmed-article:11877285pubmed:year2002lld:pubmed
pubmed-article:11877285pubmed:articleTitleALK as a novel lymphoma-associated tumor antigen: identification of 2 HLA-A2.1-restricted CD8+ T-cell epitopes.lld:pubmed
pubmed-article:11877285pubmed:affiliationOncogenic Fusion Genes and Proteins Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian 1, 20133 Milan, Italy. passoni@istitutotumori.mi.itlld:pubmed
pubmed-article:11877285pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11877285pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:238entrezgene:pubmedpubmed-article:11877285lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:11877285lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11877285lld:pubmed